CII, ICON Lead Talks on India Pharma Push Into US Manufacturing

US-based construction company ICON, in collaboration with the Confederation of Indian Industry (CII) Telangana, has successfully brought the PharmiCON, its pioneering event in India, to Hyderabad.

The event was held under the theme “Navigating the Road Ahead for US-Based Manufacturing” and was targeted to senior industry leaders, policy experts, and business stakeholders to discuss the opportunities and challenges of Indian pharmaceutical manufacturing expansion into the United States.

Sanjay Singh, Past Chairman, CII Telangana and Chakravarthi AVPS, Convener, CII Telangana Pharma and Life Sciences Panel & Chairman & MD, Ecobliss India Pvt. Ltd. emphasized the above average presence of resilience, competitiveness, etc. and also the sector's need to change its approach with the latest geopolitical and regulatory upheavals.

Bhupendra Patel, ICON’s CEO, and Founder stated once more that the company is always committed to accommodating the pharma and biotech clients with high-tech, affordable US facilities. He also added that through their 30 plus years of experience and 200 plus completed projects, over which a total of $300 million has been invested, ICON should be able to provide the required biopharmaceutical manufacturing solutions in full scope.

Also Read: Agnikul Unveils Advanced 3D Printing Rocket Factory

The event with a keynote speech by Venugopal Rao Sankineni, Vice President, Medical Devices Policy & Investments, Telangana Lifesciences, also put forward the idea that Telangana might be a very good choice for pharma and medtech startups with plans to grow at the global level.

One of the most attractive parts of the event was the launch of the whitepaper “Changing Landscape: Indian Pharma’s Move Toward US-Based Manufacturing” prepared by ICON and CII with Healthark as the knowledgeable partner.